Patent intelligence · US
US 11279703
Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
Patent details — US 11279703
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 22, 2022
- Expiration
- Mar 17, 2042
- Applicant
- APTOSE BIOSCIENCES INC.
- Claims
- 10
- CPC classes
- A61K, A61K31/498, A61K31/519, A61K45/06
Quick answer
US 11279703 (Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof) is held by APTOSE BIOSCIENCES INC.. Status: granted. Granted Mar 22, 2022. Expires Mar 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APTOSE BIOSCIENCES INC.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/498, A61K31/519, A61K45/06, A61P, A61P35/00
More from APTOSE BIOSCIENCES INC.
Related pharmaceutical patents in our USPTO index.
-
US 11149047
Aryl imidazoles for treatment of cancer
granted -
US 11104957
Compositions and methods for treating cancers
granted -
US 10080739
Aryl imidazoles and their use as anti-cancer agents
granted -
US 9567643
Compositions and methods for treating cancers
granted -
US 8987305
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
granted -
US 8969372
Aryl imidazoles and their use as anti-cancer agents
granted
Frequently asked questions
What is US patent 11279703?
US 11279703 (Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof) is held by APTOSE BIOSCIENCES INC.. Status: granted. Granted Mar 22, 2022. Expires Mar 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11279703?
APTOSE BIOSCIENCES INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11279703 expire?
Our index shows an expiration date of Mar 17, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.